Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data.

Conclusion: PC patients carrying ≥1 pathogenic DNA instability mutation, and DRD mutation carriers specifically, had higher clinical burden than non-mutation carriers. Targeted therapies for these patients are needed to reduce clinical burden and associated healthcare resource utilization. PMID: 31352849 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31352849?dopt=Abstract

Source: Journal of Medical Economics - July 31, 2019 Category: Health Management Tags: J Med Econ Source Type: research